🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "major milestone" in the battle against drug-resistant strains of the pathogen, according to health experts.

A Worldwide Public Health Issue

Cases of gonorrhoea are escalating worldwide, with data suggesting more than 82 million infections annually. Notably increased rates are reported in Africa and nations within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary advancement in the reality of rising global incidence, the spread of superbugs and the extremely scarce available drugs currently available.”

Health officials are deeply concerned about the increase in drug-resistant strains. The World Health Organization has classified it as a "priority pathogen". A tracking program revealed that the effectiveness of standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Treatment Options Gain Clearance

Zoliflodacin, alternatively called a brand name, was approved by the US FDA in mid-December for treating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Experts anticipate that focused deployment of this new drug will help slow the spread of drug resistance.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, gained clearance in concurrent days. This treatment, which is also used to treat urinary tract infections, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

This new treatment emerged from a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to develop it.

“This authorization represents a huge turning point in the therapy of superbug gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Clinical Trial Results and Worldwide Availability

Based on results released by a prominent scientific publication, the new drug cured the vast majority of uncomplicated infections. This establishes an equal footing with the current standard treatment, which combines a dual-drug approach. The research enrolled nearly 1,000 patients from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, the non-profit has the rights to license and sell the drug in numerous low-income and middle-income countries.

Medical professionals directly involved have shared positive views. The availability of a one-pill regimen such as this is hailed as a "critical tool" for managing the epidemic. This is viewed as vital to reduce the burden of the disease for patients and to prevent the spread of extremely resistant gonorrhoea worldwide.